drugset / Trial / NCT05025787

A Study to Evaluate the Safety and Efficacy of CNTX-6970 in Subjects With Knee Osteoarthritis Pain.

NCT05025787 ↗

Phase 2 Completed 55 enrolled Maurizio Fava, MD
RandomizedCrossoverQuadruple-blindTreatment

Summary

The primary objective of this study is to evaluate the safety and efficacy of CNTX-6970 for the treatment of pain related to OA of the knee compared to placebo. CNTX-6970 is being developed as a new treatment for chronic pain, including painful osteoarthritis of the knee.

Timeline

Start
2021-10-25
Primary completion
2024-06-11
Completion
2024-06-11

Outcome

Missed primary endpoint

paper trial participants reported slightly higher knee pain intensity when taking the novel chemokine antagonist CNTX-6970 than when taking placebo. PMID 41468282 ↗

paper pharmacologic blockade of specific chemokine receptors with this compound was not effective in reducing moderate-to-severe knee osteoarthritis pain. PMID 41468282 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject CNTX-6970 Small molecule 300 mg Oral

Indications